Dr. Gary Gallia's specialty is endoscopic endonasal surgical approaches to skull base pathologies with a focus on neurosurgical oncology. He utilizes the latest techniques in preoperative imaging, computer-guided surgical navigation, intraoperative monitoring, and minimally invasive and Neuroendoscopy approaches in the management of patients with benign and malignant brain tumors, metastatic tumors to the brain, skull base neoplasms, and pituitary tumors. He is the director of the Neurosurgery Skull Base Center and surgical director of the Johns Hopkins Pituitary Center. Dr. Gary Gallia graduated summa cum laude from the Gibbons Scholar MD/PhD program at Jefferson Medical College and Thomas Jefferson University. He completed his general surgery internship at The Johns Hopkins Hospital where he was awarded surgical intern of the year. He then completed his neurological surgery residency and a postdoctoral fellowship in neuro-oncology at The Johns Hopkins Hospital. Following residency, he completed a minimally invasive and endoscopic neurosurgery fellowship with Dr. Charles Teo at the Prince of Wales Private Hospital and Sydney Children's Hospital in Sydney, Australia. Dr. Gallia is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Olfactory Neuroblastoma, Chordoma, Pituitary Tumor, Endoscopic Transnasal Transsphenoidal Surgery, and Awake Craniotomy.

Dr. Tanguy Seiwert is an oncologist in Baltimore, caring for patients with head and neck cancer. He serves as the director of the Head and Neck Cancer Oncology Disease Program and the co-director of the Bloomberg~Kimmel Institute for Immunotherapy at the Head and Neck Cancer Program at the Johns Hopkins School of Medicine. Dr. Seiwert earned his M.D. at Johannes Gutenberg Universität in Mainz, Germany. He completed his residency at the Duke University School of Medicine and performed a fellowship in hematology/oncology at the University of Chicago Medicine Mitchell Hospital-Hyde Park. Dr. Seiwert joined the Johns Hopkins faculty in 2019. Prior to joining Johns Hopkins, Dr. Seiwert was director of the Head and Neck Cancer Program at the University of Chicago. Dr. Seiwert’s research interests include immunologic and genomic profiling. He has given numerous invited talks on head and neck cancer both nationally and internationally. Dr. Seiwert served as chief editor for Frontiers in Head and Neck Cancer and as an editorial board member for the Journal of Clinical Oncology and Oral Oncology. He is a reviewer for multiple medical journals, including Lancet Oncology, Annals of Oncology and Clinical Cancer Research. He has been recognized by the American Association for Clinical Oncology for multiple Merit Awards and a Young Investigator Award. He was a member of the NCI Head and Neck Cancer Steering Committee, and is a member of the American Association for Clinical Oncology, the Society for Immunotherapy of Cancer, and the European Society of Clinical Oncology. Dr. Seiwert is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Glioma, Laryngeal Cancer, Tongue Cancer, Oral Squamous Cell Carcinoma, and Gastrostomy.

Dan Kunaprayoon is a Radiation Oncologist in Columbia, Maryland. Dr. Kunaprayoon is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Breast Cancer, and Pleuropulmonary Blastoma.

Peter Graze is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Graze is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Graze is currently accepting new patients.

Stuart Selonick is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Selonick is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Idiopathic Neutropenia, and Lung Cancer. Dr. Selonick is currently accepting new patients.

Pradip Amin is a Radiation Oncologist in Columbia, Maryland. Dr. Amin is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, ALK-Positive Non-Small Cell Lung Cancer, and EGFR Positive Lung Cancer.

Kevin Cullen is an Oncologist in Baltimore, Maryland. Dr. Cullen is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Olfactory Neuroblastoma, Teratocarcinosarcoma, and Laryngeal Cancer. Dr. Cullen is currently accepting new patients.

Rodney Taylor is an Otolaryngologist in Baltimore, Maryland. Dr. Taylor is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Teratocarcinosarcoma, Olfactory Neuroblastoma, Sinus Cancer, Laryngectomy, and Tissue Biopsy.

Samir Kanani is a Radiation Oncologist in Laurel, Maryland. Dr. Kanani is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor. Dr. Kanani is currently accepting new patients.

Dr. Harry Quon is an associate professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also holds appointments in oncology and in otolaryngology - head and neck surgery. His area of clinical expertise is radiation treatment for head and neck cancers. He serves as the co-director of the Johns Hopkins Head and Neck Cancer Multidisciplinary Clinic. Dr. Quon received his M.D. from the University of Toronto Institute of Medical Science. He completed his residency at the Princess Margaret Hospital in Ontario and performed a fellowship in radiation oncology at the Princess Margaret Hospital and the Beth Israel Medical Center. Make A Gift. Dr. Quon is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Dry Mouth, Gastrostomy, and Prostatectomy.

Wayne Koch is a national and international leader in head and neck oncologic surgery, caring for patients with cancers of the oral cavity, salivary gland, larynx, hypopharynx, oropharynx and thyroid. Among Dr. Koch's landmark publications are studies demonstrating how key molecular events such as p53 mutation and human papillomavirus (HPV) contribute to the development of head and neck cancer. His peer-reviewed publications include six articles in the New England Journal of Medicine. Dr. Koch is also involved in humanitarian outreach focused on training surgeons in several African nations. He has served as president of the American Head and Neck Society, the national organization of head and neck cancer surgeons in the USA. Dr. Koch is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Human Papillomavirus Infection, Laryngectomy, and Gastrostomy.

Dr. Ana Kiess's clinical focus is on the treatment of prostate cancer and head and neck cancers with external beam radiotherapy and radiopharmaceutical therapies. Her research concentrates on the integration of new radiopharmaceutical therapies and dosimetry techniques into the clinic. Dr. Kiess received her bachelors of science degree in chemical engineering from the University of Virginia, after which she obtained a doctorate of medicine and a doctorate of philosophy degree in biomedical engineering from Duke University. Following medical school, she matriculated to the resident staff at Memorial Sloan Kettering Cancer Center, receiving extensive oncologic training and research experience. She also completed a postdoctoral research fellowship at Johns Hopkins University in the Department of Radiology. Make A Gift. Dr. Kiess is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Prostate Cancer, Laryngeal Cancer, Throat Cancer, Gastrostomy, and Adenoidectomy.

Ranee Mehra is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mehra is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Tongue Cancer, and Glossectomy. Dr. Mehra is currently accepting new patients.

William Regine is a Radiation Oncologist in Baltimore, Maryland. Dr. Regine is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Pancreatic Cancer, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Anal Cancer.

Bert O'malley is an Otolaryngologist in Baltimore, Maryland. Dr. O'malley is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Pituitary Tumor, Salivary Gland Tumors, Sinus Cancer, Endoscopic Transnasal Transsphenoidal Surgery, and Gastrostomy. Dr. O'malley is currently accepting new patients.

Jeffrey Wolf is an Otolaryngologist in Baltimore, Maryland. Dr. Wolf is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Acinic Cell Carcinoma of Salivary Glands, Thyroidectomy, and Gastrostomy. Dr. Wolf is currently accepting new patients.

Kyle Hatten is an Otolaryngologist in Baltimore, Maryland. Dr. Hatten is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Tongue Cancer, Salivary Gland Tumors, Laryngeal Cancer, Laryngectomy, and Gastrostomy. Dr. Hatten is currently accepting new patients.

Christine Gourin, M.D. M.P.H., is a head and neck surgical oncologist and palliative medicine specialist who treats patients with head and neck tumors, including tumors of the skin, melanoma, oral cavity, larynx, oropharynx, neck, salivary glands, sinuses, and skull base. Dr. Gourin received her medical degree from the State University of New York-Health Science Center at Brooklyn/Downstate Medical Center. Dr. Gourin trained in General Surgery and Otolaryngology-Head and Neck Surgery at the University of Vermont, followed by a fellowship in Advanced Head and Neck Oncologic Surgery at the University of Pittsburgh and a fellowship in Hospice and Palliative Medicine at Johns Hopkins University. She has authored over 200 peer-reviewed journal articles, 24 book chapters and two books: Medical and Surgical Management of Thyroid and Parathyroid Diseases and The Johns Hopkins Patient Guide to Head and Neck Cancer. She is on the Editorial Board of The Laryngoscope and is a reviewer for numerous other head and neck surgery journals. Dr. Gourin is a nationally and internationally recognized expert in quality of care and outcomes with a lifelong interest in improved symptom management, communication, access to high-quality affordable care, and palliative medicine in head and neck cancer. She has an active head and neck surgical oncology practice and has been named to America’s Top Physicians and Best Doctors in America annually since 2005. She is the Director of the Johns Hopkins Head and Neck Cancer Supportive Care Clinic. Dr. Gourin is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Laryngeal Cancer, Throat Cancer, Tongue Cancer, Laryngectomy, and Gastrostomy.

Dr. Kofi Derek Owusu Boahene is a professor of otolaryngology-head and neck surgery and dermatology at the Johns Hopkins University School of Medicine. He is the Director of the Division of Facial Plastics and Reconstructive Surgery and the director for the facial plastics fellowship training program. His practice encompasses the entire spectrum of facial plastic and reconstructive surgery including cosmetic and reconstructive aspects. Dr. Boahene is a leading expert in facial paralysis surgery and facial nerve injuries and has pioneered innovative treatment protocols and surgical techniques in facial reanimation. He is the director of the Johns Hopkins Facial Nerve center dedicated to restoring facial balance, symmetry and animation to those who have suffered from facial paralysis and facial nerve disorders. As an expert microsurgeon, Dr. Boahene routinely performs some of the most complex facial reconstruction procedures on the face including rebuilding of an entire nose, lip, jaw and facial defects resulting from cancer treatment, traumatic injuries or as a result of birth defects. He uses cutting edge 3-D technology, image-guided technology and tissue transplanted from other parts of the body to restore or replace missing tissues. He is a key member of the Johns Hopkins facial transplant program. His cosmetic experience is broad and draws from patients across the globe. He routinely performs rhinoplasties, eyelid surgery, face lifts and other facial enhancing procedures. As a skull base surgeon, Dr. Boahene has pioneered minimally invasive techniques for removal of skull base and brain tumors, repairing CSF leaks and has authored a major textbook on this subject. Dr. Boahene received his undergraduate degree from the University of Central Arkansas. He graduated summa cum laude from Meharry Medical College in Nashville, Tennessee, completed a five-year surgical residency training program in otolaryngology-head and neck surgery at the Mayo Clinic in Rochester, Minnesota, and received fellowship training in facial plastic and reconstructive surgery at the University of Minnesota. As the recipient of the prestigious Mayo Brothers Distinguished Fellowship Award, Dr. Boahene was awarded additional craniofacial surgery training in Adelaide, Australia. He also received the Jack R. Anderson Prize for Scholastic Excellence for attaining the highest score nationally on the American Academy of Facial Plastic and Reconstructive Surgery certification exam. Dr. Boahene serves as on the Board of Governors or the American Academy Facial Plastic and Reconstructive Surgery. He is a member of several professional organizations, including the American Academy of Facial Plastic and Reconstructive Surgery and the American Academy of Otolaryngology-Head and Neck Surgery. In 1993, Dr. Kofi Boahene received the Alpha Omega Alpha Medical. Dr. Boahene is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Facial Paralysis, Bell's Palsy, Recurrent Peripheral Facial Palsy, Septoplasty, and Gastrostomy.

Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.